 Nurix Therapeutics Inc. shares fell 2.3 in their trading debut Friday, after pricing above the proposed price range. Nurix sold 11 million shares priced at 19 each, above a recently tweaked 17 to 18 range. Its original plan was to sell 8.8 million shares priced at 16 to 18. The shares are trading on Nasdaq, under the ticker NRIX. JPMorgan, Piper Sandler, Stifel and Needham Co. were underwriters on the deal. Proceeds will be used to fund clinical research and RD, as well as for working capital and general corporate purposes. We are a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders, the company says in its prospectus. The IPO market has been strong recently and the Renaissance IPO ETF has gained 33 in the year to date, outperforming the SP 500 , which is down 0.7. 